JP2004536824A - Ｓ．ｍｕｔａｎｓに対するヒト化モノクローナル抗体を作製するためのＤＮＡ分子および組換えＤＮＡ分子 - Google Patents

Ｓ．ｍｕｔａｎｓに対するヒト化モノクローナル抗体を作製するためのＤＮＡ分子および組換えＤＮＡ分子 Download PDF

Info

Publication number
JP2004536824A
JP2004536824A JP2003506430A JP2003506430A JP2004536824A JP 2004536824 A JP2004536824 A JP 2004536824A JP 2003506430 A JP2003506430 A JP 2003506430A JP 2003506430 A JP2003506430 A JP 2003506430A JP 2004536824 A JP2004536824 A JP 2004536824A
Authority
JP
Japan
Prior art keywords
antibody
treating
dental caries
variable region
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003506430A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004536824A5 (https=
Inventor
シ，ウェンユアン
モリソン，シェリー，エル．
トリンフ，クハム
ウィムズ，レティシア
チェン，リ
アンダーソン，マックスウェル，エイチ．
Original Assignee
シー３ サイエンティフィック コーポレーション
ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シー３ サイエンティフィック コーポレーション, ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア filed Critical シー３ サイエンティフィック コーポレーション
Publication of JP2004536824A publication Critical patent/JP2004536824A/ja
Publication of JP2004536824A5 publication Critical patent/JP2004536824A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C12N15/8258—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon for the production of oral vaccines (antigens) or immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1275—Streptococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2003506430A 2001-06-15 2002-06-11 Ｓ．ｍｕｔａｎｓに対するヒト化モノクローナル抗体を作製するためのＤＮＡ分子および組換えＤＮＡ分子 Pending JP2004536824A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/881,823 US20020068066A1 (en) 1999-08-20 2001-06-15 Method for the treatment and prevention of dental caries
PCT/US2002/018692 WO2002102975A2 (en) 2001-06-15 2002-06-11 Dna molecules and recombinant dna molecules for producing humanized monoclonal antibodies to s. mutans

Publications (2)

Publication Number Publication Date
JP2004536824A true JP2004536824A (ja) 2004-12-09
JP2004536824A5 JP2004536824A5 (https=) 2005-09-22

Family

ID=25379292

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003506430A Pending JP2004536824A (ja) 2001-06-15 2002-06-11 Ｓ．ｍｕｔａｎｓに対するヒト化モノクローナル抗体を作製するためのＤＮＡ分子および組換えＤＮＡ分子

Country Status (6)

Country Link
US (1) US20020068066A1 (https=)
EP (1) EP1434799A4 (https=)
JP (1) JP2004536824A (https=)
AU (1) AU2002318342A2 (https=)
CA (1) CA2448506A1 (https=)
WO (1) WO2002102975A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7569542B2 (en) 1999-08-20 2009-08-04 The Regents Of The University Of California Anti-microbial targeting chimeric pharmaceutical
US20030143234A1 (en) * 1999-08-20 2003-07-31 Wenyuan Shi Anti-microbial targeting chimeric pharmaceutical
US7875598B2 (en) * 2004-03-04 2011-01-25 The Regents Of The University Of California Compositions useful for the treatment of microbial infections
CA2661634C (en) 2006-09-06 2017-03-28 The Regents Of The University Of California Selectively targeted antimicrobial peptides and the use thereof
ES2548767T3 (es) * 2007-01-16 2015-10-20 The Regents Of The University Of California Nuevos péptidos antimicrobianos
AU2014203172B2 (en) * 2010-02-24 2016-03-10 Immunogen, Inc. Folate Receptor 1 Antibodies and Immunoconjugates and Uses Thereof
TWI622402B (zh) 2010-02-24 2018-05-01 免疫遺傳股份有限公司 葉酸受體１抗體類和免疫共軛物類及彼等之用途
CL2011003002A1 (es) * 2011-11-25 2012-05-25 Univ Pontificia Catolica Chile Anticuerpo monoclonal o un fragmento del mismo que se une a la proteina m2-1 del virus respiratorio sincicial (vrs) humano; secuencias nucleotidicas; composicion farmaceutica; metodo de diagnostico de infeccion producida por vrs; kit; y uso de dicho anticuerpo para preparar un medicamento.
WO2016049183A1 (en) * 2014-09-24 2016-03-31 Aerpio Therapeutics, Inc. Ve-ptp extracellular domain antibodies delivered by a gene therapy vector
BR112019001206A2 (pt) * 2016-07-20 2019-06-25 Aerpio Therapeutics Inc anticorpos monoclonais humanizados que visam ve-ptp (hptp-ss)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9014932D0 (en) * 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
EP1400536A1 (en) * 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US6046037A (en) * 1994-12-30 2000-04-04 Hiatt; Andrew C. Method for producing immunoglobulins containing protection proteins in plants and their use
JP4731687B2 (ja) * 1998-08-21 2011-07-27 ザ リージェンツ オブ ザ ユニヴァーシティ オブ カリフォルニア ストレプトコッカス・ミュータンスに特異的なモノクロナール抗体、およびその使用
JP2004506695A (ja) * 2000-08-24 2004-03-04 ワシントン　デンタル　サービス う蝕の予防の免疫学的方法

Also Published As

Publication number Publication date
WO2002102975A3 (en) 2004-04-15
US20020068066A1 (en) 2002-06-06
WO2002102975A2 (en) 2002-12-27
EP1434799A2 (en) 2004-07-07
EP1434799A4 (en) 2005-10-05
CA2448506A1 (en) 2002-12-27
AU2002318342A2 (en) 2003-01-02

Similar Documents

Publication Publication Date Title
US6417429B1 (en) Transgenic plants expressing assembled secretory antibodies
Abiko Passive immunization against dental caries and periodontal disease: development of recombinant and human monoclonal antibodies
DE69033676T2 (de) Zusammensetzungen, die von pflanzen produzierte glykopolypeptidmultimere enthalten, sowie verfahren zu deren herstellung
US10894818B2 (en) Antibodies that bind Ebola glycoprotein and uses thereof
RU2653430C2 (ru) Антагонистические антитела против рецептора IL-7 и способы
US20060258848A1 (en) Human antipneumococcal antibodies from non-human animals
US8491907B2 (en) Human anti-Pseudomonas-aeruginosa It-2 antibodies derived from transgenic xenomouse
US8986990B2 (en) Human antibodies against Pseudomonas aeruginosa LPS
CA2303202C (en) Amino acid sequences for therapeutical and prophylactic applications to diseases due to clostridium difficile toxins
JPH06501152A (ja) 動物およびヒトにおける感染の治療および予防用の新規な抗体
US20080199463A1 (en) Method for treating multiple myeloma
US7005560B1 (en) Transgenic plants expressing assembled secretory antibodies
KR20100014476A (ko) Ｃ형 간염 바이러스(ｈｃｖ)에 대한 인간 항체 및 이것의 용도
JP2004536824A (ja) Ｓ．ｍｕｔａｎｓに対するヒト化モノクローナル抗体を作製するためのＤＮＡ分子および組換えＤＮＡ分子
WO2002015931A1 (en) Immunologic method for the prevention of dental caries
EP0781337A1 (fr) Anticorps humanise dirige contre la chaine beta 1 des integrines
AU2004236263A1 (en) Compositions and methods for treatment of cryptococcosis
US6995014B1 (en) Transgenic plants expressing assembled secretory antibodies
KR101388680B1 (ko) 광견병 바이러스를 중화시킬 수 있는 결합 분자
JP2002114709A (ja) 虫歯予防剤
AU2007216785A1 (en) Human Antibodies Against Pseudomonas Aeruginosa LPS Derived from Transgenic Xenomouse
AU2001288866A1 (en) Human antibodies against pseudomonas aeruginosa LPS derived from transgenic xenomouse
MXPA00002491A (en) Amino acid sequences for therapeutical and prophylactic applications to diseases due to clostridium difficile
MXPA05011989A (en) Compositions and methods for treatment of cryptococcosis